Dr Mark Ware, Chief Medical Officer of Canopy Growth and speaker at MedCan Summit 2020, is a Canadian pain specialist.
“Why is it important to have a well-regulated medical pathway for medicinal cannabis, especially in markets, like Canada, that have legalised cannabis for adult use?”
Dr Ware: Firstly, patients as well their doctors and pharmacists deserve to have access to safe and effective medicinal cannabis products that are produced in the same way as their other pharmaceutical products. Patients and health professionals need guidance on titration and dosing while ensuring that the levels of the medically important cannabinoids THC and CBD that appear on product labels are accurate and standardised.
Cannabis isn’t a one-size-fits-all therapy. It is a complex plant, and people react to it in many different ways. Finding an appropriate product for a patient’s symptoms is often a matter of informed trial and error between the patient and their doctor.
Finally, as I mentioned, prohibition has restricted our ability to undertake research. Research conducted thus far has shown a great deal of potential for a wide range of indications and we have only just scratched the surface.
This is an extract from an interview with Health Central NZ. Read the full interview here.
Spectrum Therapeutics is a silver sponsor of MedCan Summit 2020.